Sildenafil improves exercise capacity in patients with cystic fibrosis: a proof-of-concept clinical trial

BACKGROUND: Exercise intolerance is a common phenotype observed in patients with cystic fibrosis (CF). Treatment with sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, has previously been shown to improve exercise capacity (VO(2) peak) in other patient populations. Thus, the present study sou...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez-Miguelez, Paula, Ishii, Haruki, Seigler, Nichole, Crandall, Reva, Thomas, Jeffrey, Forseen, Caralee, McKie, Kathleen T., Harris, Ryan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876159/
https://www.ncbi.nlm.nih.gov/pubmed/31803404
http://dx.doi.org/10.1177/2040622319887879

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876159/
https://www.ncbi.nlm.nih.gov/pubmed/31803404
http://dx.doi.org/10.1177/2040622319887879

Ejemplares similares